Overall Assessment: The stock has been in a severe downtrend over the observed six-month period, with the price collapsing from around $46 in October 2025 to $25.65 by March 31, 2026. This represents a decline of approximately 44.6% over six months, significantly underperforming the broader market (SPY down 2.82%). The trend is decisively bearish.

Short-term Performance: The stock has experienced extreme weakness in the short term. The 1-month price change is -38.75%, and the 3-month change is -40.29%, both far worse than the SPY's performance of -5.25% and -4.63%, respectively. The most recent trading session saw a drop of 9.27% from $28.27 to $25.65.

Current Position: The current price of $25.65 is very close to its 52-week low of $24.72 and far from its 52-week high of $65.5, placing it near the bottom of its annual range. The stock's beta of 0.568 suggests it is less volatile than the market, but it has exhibited extreme downside volatility recently.

Revenue & Profitability: Revenue for Q1 2026 was $247.8 million, showing a year-over-year growth of 4.11% from the prior year's Q1. Net income for the quarter was $22.8 million, resulting in a net margin of 9.2%, which is a significant improvement from the 4.6% net margin in Q1 2025. The company maintains a strong gross margin of 82.3%.

Financial Health: The company's debt-to-equity ratio is high at 1.78, indicating a leveraged balance sheet. However, it generated strong operating cash flow of $98.6 million in the latest quarter and has a trailing twelve-month free cash flow of $257.7 million, suggesting solid cash generation to service its debt.

Operational Efficiency: Return on Equity (ROE) is reported at 15.3%, which is a healthy level of profitability relative to shareholder equity. The current ratio is low at 0.49, indicating potential liquidity constraints in covering short-term obligations with current assets.